A one-step synthetic procedure using the reaction of potassium bis(oxalato)platinate(II) with the corresponding N6-benzyladenosine derivative (nL) provided the [Pt(ox)(nL)₂]∙1.5H₂O oxalato (ox) complexes 1-5, involving the nL molecules as monodentate coordinated N-donor ligands. The complexes were thoroughly characterized by elemental analysis, multinuclear (¹H, ¹³C, ¹⁵N, 1¹⁹⁵Pt) and two dimensional NMR, infrared and Raman spectroscopy, and mass spectrometry, proving their composition and purity as well as coordination of nL through the N7 atom of the purine moiety. Geometry of [Pt(ox)(4FL)₂] (5) was optimized at the B3LYP/LANLTZ/6-311G** level of theory. The complexes were screened for their in vitro cytotoxicity against two human cancer cell lines (HOS osteosarcoma and MCF7 breast adenocarcinoma), but they did not show any effect up to the concentration of 50.0 µM (compounds 1, 2) or 20.0 µM (compounds 3-5).

Regional Centre of Advanced Technologies and Materials Department of Inorganic Chemistry Faculty of Science Palacký University 17 listopadu 12 CZ 77146 Olomouc Czech Republic

Zobrazit více v PubMed

Kelland L.R., Farrell N.P. Platinum based Drugs in Cancer Therapy. Humana Press; Totowa, New Jersey, NJ, USA: 2000.

Bose R.N., Cornelius R.D., Viola R.E. Multinuclear NMR studies and the kinetics of formation of platinum(II)-adenine nucleotide complexes. J. Am. Chem. Soc. 1986;108:4403–4408. doi: 10.1021/ja00275a029. DOI

Fichtinger–Schepman A.M.J., van der Veer J.L., den Hartog J.H.J., Lohman P.H.M., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation. Biochemistry. 1985;24:707–713. PubMed

Cleare M.J., Hoeschele J.D. Studies on the antitumor activity of group VIII transition metal complexes Part I Platinum(II) Complexes. Bioinorg. Chem. 1973;2:187–210. doi: 10.1016/S0006-3061(00)80249-5. DOI

Štarha P., Popa I., Trávníček Z., Vančo J. N6-Benzyladenosine derivatives as novel N-donor ligands of platinum(II) dichlorido complexes. Molecules. 2013;18:6990–7003. doi: 10.3390/molecules18066990. PubMed DOI PMC

Trávníček Z., Štarha P., Popa I., Vrzal R., Dvořák Z. Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: Preparation, characterization and in vitro cytotoxicity. Eur. J. Med. Chem. 2010;45:4609–4614. doi: 10.1016/j.ejmech.2010.07.025. PubMed DOI

Trávníček Z., Matiková-Maľarová M., Novotná R., Vančo J., Štěpánková K., Suchý P. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A. J. Inorg. Biochem. 2011;105:937–948. doi: 10.1016/j.jinorgbio.2011.04.002. PubMed DOI

Trávníček Z., Štarha P., Vančo J., Šilha T., Hošek J., Suchý P., Pražanová G. Anti-inflammatory active gold(I) complexes involving 6-substituted purine derivative. J. Med. Chem. 2012;55:4568–4579. doi: 10.1021/jm201416p. PubMed DOI

Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997;243:527–536. PubMed

Benson C., Kaye S., Workman P., Garret M., Walton M., de Bono J. Clinical anticancer drug development: Targeting the cyclin-dependent kinases. Br. J. Cancer. 2005;92:7–12. doi: 10.1038/sj.bjc.6602229. PubMed DOI PMC

Vrzal R., Štarha P., Dvořák Z., Trávníček Z. Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands. J. Inorg. Biochem. 2010;104:1130–1132. doi: 10.1016/j.jinorgbio.2010.07.002. PubMed DOI

Szüčová L., Trávníček Z., Popa I., marek J. Preparation and cis-to-trans transformation study of square-planar [Pt(Ln)2Cl2] complexes bearing cytokinins derived from 6-benzylaminopurine (Ln) by view of NMR spectroscopy and X-ray crystallography. Polyhedron. 2008;27:2710–2720.

Dvořák L., Popa I., Štarha P., Trávníček Z. In vitro cytotoxic-active platinum(II) complexes derived from carboplatin and involving purine derivatives. Eur. J. Inorg. Chem. 2010:3441–3448.

Doležal K., Popa I., Hauserová E., Spíchal L., Chakrabarty K., Novák O., Kryštof V., Voller J., Holub J., Strnad M. Preparation, biological activity and endogenous occurrence of N6-benzyladenosines. Bioorg. Med. Chem. 2007;15:3737–3747. doi: 10.1016/j.bmc.2007.03.038. PubMed DOI

Nakamoto K. Infrared and Raman Spectra of Inorganic and Coordination Compounds. 5th ed. Willey-Interscience; New York, NY, USA: 1997.

Pouchert C.J. The Aldrich Library of Infrared Spectra. Aldrich Chemical Company Press; Milwaukee, WI, USA: 1981.

Malek K., Podstawka E., Milecki J., Schroeder G., Proniewicz L.M. Structural features of the adenosine conjugate in means of vibrational spectroscopy and DFT. Biophys. Chem. 2009;142:17–26. doi: 10.1016/j.bpc.2009.02.007. PubMed DOI

Čajan M., Trávníček Z. Structural (X-ray), spectral (FT-IR and Raman) and quantum chemical investigations of a series of 6-benzylaminopurine derivatives. J. Mol. Struct. 2011;994:350–359. doi: 10.1016/j.molstruc.2011.03.049. DOI

Liu J., Cao S., Jia B., Wei D., Liao X., Lu J., Zhao Y. A theoretical and mass spectrometry study of the novel mechanism of N-glycosidic bond cleavage in nukleoside. Int. J. Mass. Spectrom. 2009;282:1–5. doi: 10.1016/j.ijms.2009.01.003. DOI

Grimme S. Accurate description of van der Waals complexes by density functional theory including empirical corrections. J. Comput. Chem. 2004;25:1463–1476. doi: 10.1002/jcc.20078. PubMed DOI

Grimme S. Semiempirical GGA-type density functional constructed with a long-range dispersion correction. J. Comput. Chem. 2006;27:1787–1799. doi: 10.1002/jcc.20495. PubMed DOI

Lee C., Yang W., Parr R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B. 1988;37:785–789. doi: 10.1103/PhysRevB.37.785. PubMed DOI

Feller D. The role of databases in support of computational chemistry calculations. J. Comp. Chem. 1996;17:1571–1586. doi: 10.1002/(SICI)1096-987X(199610)17:13<1571::AID-JCC9>3.0.CO;2-P. DOI

Schuchardt K.L., Didier B.T., Elsethagen T., Sun L., Gurumoorthi V., Chase J., Li J., Windus T.L. Basis set exchange: a community database for computational sciences. J. Chem. Inf. Model. 2007;47:1045–1052. doi: 10.1021/ci600510j. PubMed DOI

Krishnan R., Binkley J.S., Seeger R., Pople J.A. Self‐consistent molecular orbital methods. XX. A basis set for correlated wave functions. J. Chem. Phys. 1980;72:650–654. doi: 10.1063/1.438955. DOI

Neese F. ORCA — An ab initio, Density Functional and Semiempirical Program Package. Universität Bonn; Bonn, Germany: 2010. Version 2.8.

Rochon F.D., Melanson R., Macquet J.P., Belanger-Gariepy F., Beauchamp A.L. Crystal structures of diammine(oxalato)platinum(II)and diammine(malonato)platinum(II) Inorg. Chim. Acta. 1985;108:1–6. doi: 10.1016/S0020-1693(00)84314-5. DOI

Štarha P., Marek J., Trávníček Z. Cisplatin and oxaliplatin derivatives involving 7-azaindole: Structural characterisations. Polyhedron. 2012;33:404–409. doi: 10.1016/j.poly.2011.11.059. DOI

Štarha P., Trávníček Z., Popa I. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity. J. Inorg. Biochem. 2010;104:639–647. doi: 10.1016/j.jinorgbio.2010.02.005. PubMed DOI

Meelich K., Galanski M., Arion V.B., Keppler B.K. Bis(2-amino alcohol-κN)dicarboxylatoplatinum(II) complexes — elegant synthesis via ring-opening of bis(2-amino alcoholato-κ2N, O)platinum(II) species with dicarboxylic acids. Eur. J. Inorg. Chem. 2006:2476–2483.

Allen F.A. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr. 2002;B58:380–388. doi: 10.1107/S0108768102003890. PubMed DOI

Mikola M., Klika K.D., Arpalahti J. The Kinetics of substitution reactions of mixed platinum(II)–bis(nucleoside) complexes in aqueous solution in the presence of thiourea; X-ray crystal structure determination of cis-[Pt(NH3)2(adenosine-N7)2](ClO4)2∙3.5H2O. Chem. Eur. J. 2000;6:3404–3413. doi: 10.1002/1521-3765(20000915)6:18<3404::AID-CHEM3404>3.0.CO;2-R. PubMed DOI

Mueller H., Kassack M.U., Wiese M. Comparison of the usefulness of the MTT, ATP, and Calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J. Biomol. Screen. 2004;9:506–515. doi: 10.1177/1087057104265386. PubMed DOI

Klein A.V., Hambley T.W. Platinum drug distribution in cancer cells and tumors. Chem. Rev. 2009;109:4911–4920. doi: 10.1021/cr9001066. PubMed DOI

Siddik Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279. doi: 10.1038/sj.onc.1206933. PubMed DOI

Berners-Price S.J., Ronconi L., Sadler P.J. Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 2006;49:65–98. doi: 10.1016/j.pnmrs.2006.05.002. DOI

Kuhnle J.A., Fuller G., Corse J., Mackey B.E. Anti-senescent activity of natural cytokinins. Physiol. Plant. 1977;41:14–21. doi: 10.1111/j.1399-3054.1977.tb01514.x. DOI